Skip to main content
NIPH logo
SeroSelectTB logo with financing logos.png

SeroSelectTB

Project

|

Updated

SeroSelectTB is a multinational project coordinated by the Norwegian Institute of Public Health.

Summary

The performance of a new triage test for active tuberculosis, SeroSelectTB, will be qualified in multi-centre randomised controlled trials at health-posts in South Africa, Tanzania and Ethiopia. Cost effectiveness evaluations will be conducted to support a value proposition to stakeholders and regulatory authorities, and to support commercialization requirements. Consenting adults will provide blood and saliva samples for screening by SeroSelectTB, and sputum collected for routine TB diagnosis by the health services. Clinical and sociodemographic information will be collected. A reliable rapid test will make it possible to identify and selectively treat those with active TB at the local healthcare level. The expected impact includes accurate same-day diagnosis of patients with active TB, reduction of diagnostic delay and TB transmission, and diagnostic cost-savings for patients and healthcare systems in high burden countries.

SeroSelectTB is a multinational project coordinated by the Norwegian Institute of Public Health (Oslo, Norway). Partners include Stellenbosch University and Lateral Flow Laboratories (South Africa), Kilimanjaro Christian Medical University College (Tanzania), Armauer Hansen Research Institute (Ethiopia), KNCV Tuberculosis Foundation (Netherlands), InVivo Biotech Services GmbH (Germany), and Aether Dynamics Consulting & Trading GmbH (Austria).  

Project leader

Carol Joanne Church Holm-Hansen, Norwegian Institute of Public Health

Project participants

Aida Babaii, Researc Administrative Support, Norwegian Institute of Public Health
Ida Laake, Infection Control, Norwegian Institute of Public Health
Grant Theron, Stellenbosch University
Balthazar Nyombi, Kilimanjaro Christian Medical University College
Kidist Bobosha, AHRI Armauer Hansen Research Institute
Kristin Kremer, KNCV Tuberculosisfoundation
Nick Borain, Lateral Flow Laboratories (Pty) Ltd
Tim Welsink, InVivo Biotech Services GmbH
Aleksandar Josifoski, Aether Dynamics Consulting and Trading GmbH
Miloje Savic, Aether Dynamics Consulting and Trading GmbH

Start

01.01.2020

End

31.12.2025

Status

Active

Financing

European and Developing Countries Clinical Trials Partnership (EDCTP) grant code: RIA2018D-2493

Approvals

Regional committees for medical and health research ethics

Project owner/ Project manager

Norwegian Institute of Public Health

Participant at FHI

Aida Babaii

Ida Laake

Published |Updated